Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist. Tall Bull S, Nuffer W, Trujillo JM. J Diabetes Complications 2022;36:108332.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tall Bull S, Nuffer W, Trujillo JM. Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist. J Diabetes Complications 2022;36:108332.
PMID: 36375235